Evidence map›Paper›PMID 29357840›Full record

ArticleBMC cancer2018

FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X

Paula Maciel-Silva, Izabela Caldeira, Icaro de Assis Santos, Ana Claudia Oliveira Carreira, Flavia Ramos Siqueira, Eliane Antonioli, Anna Carla Goldberg, José Ernesto Belizário, Humberto Miguel Garay-Malpartida

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. International journal of general medicine · 2022
    Article
  11. The cytokine FAM3B/PANDER is an FGFR ligand that promotes posterior development inProceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  12. Upregulation of FAM3B Promotes Cisplatin Resistance in Gastric Cancer by Inducing Epithelial-Mesenchymal Transition.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Paula Maciel-SilvaSchool of Arts, Sciences and Humanities, University of São Paulo, São Paulo, SP, Brazil.
Izabela CaldeiraSchool of Arts, Sciences and Humanities, University of São Paulo, São Paulo, SP, Brazil.
Icaro de Assis SantosSchool of Arts, Sciences and Humanities, University of São Paulo, São Paulo, SP, Brazil.
Ana Claudia Oliveira CarreiraDepartment of Internal Medicine, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
Flavia Ramos SiqueiraDepartment of Internal Medicine, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
Eliane AntonioliHospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Anna Carla GoldbergHospital Israelita Albert Einstein, São Paulo, SP, Brazil.
José Ernesto BelizárioDepartment of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, SP, Brazil.
Humberto Miguel Garay-MalpartidaSchool of Arts, Sciences and Humanities, University of São Paulo, São Paulo, SP, Brazil. hmgaray@usp.br.
Universidade de São Paulo · BRHospital Israelita Albert Einstein · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2007/04513-1
6 · The paper itself

Abstract

backgroundFAM3B/PANDER is a novel cytokine-like protein that induces apoptosis in insulin-secreting beta-cells. Since in silico data revealed that FAM3B can be expressed in prostate tumors, we evaluated the putative role of this cytokine in prostate tumor progression.

methodsFAM3B expression was analyzed by quantitative PCR in tumor tissue clinical samples and prostate tumor cell lines. Culture growth and viability of DU145 cell line were evaluated after treatment with either exogenous FAM3B protein obtained from conditioned media (CM) of 293 T cells overexpressing FAM3B or a recombinant FAM3B protein produced in a bacterial host. DU145 cells overexpressing FAM3B protein were produced by lentiviral-mediated transduction of full-length FAM3B cDNA. Cell viability and apoptosis were analyzed in DU145/FAM3B cells after treatment with several cell death inducers, such as TNF-alpha, staurosporine, etoposide, camptothecin, and serum starvation conditions. Anchorage-independent growth in soft agarose assay was used to evaluate in vitro tumorigenicity. In vivo tumorigenicity and invasiveness were evaluated by tumor xenograft growth in nude mice.

resultsWe observed an increase in FAM3B expression in prostate tumor samples when compared to normal tissues. DU145 cell viability and survival increased after exogenous treatment with recombinant FAM3B protein or FAM3B-secreted protein. Overexpression of FAM3B in DU145 cells promoted inhibition of DNA fragmentation and phosphatidylserine externalization in a time and dose-dependent fashion, upon apoptosis triggered by TNF-alpha. These events were accompanied by increased gene expression of anti-apoptotic Bcl-2 and Bcl-XL, decreased expression of pro-apoptotic Bax and diminished caspase-3, -8 and -9 proteolytic activities. Furthermore, inhibition of Bcl-2 anti-apoptotic family proteins with small molecules antagonists decreases protective effects of FAM3B in DU145 cells. When compared to the respective controls, cells overexpressing FAM3B displayed a decreased anchorage- independent growth in vitro and increased tumor growth in xenografted nude mice. The immunohistochemistry analysis of tumor xenografts revealed a similar anti-apoptotic phenotype displayed by FAM3B-overexpressing tumor cells.

conclusionsTaken together, by activating pro-survival mechanisms FAM3B overexpression contributes to increased resistance to cell death and tumor growth in nude mice, highlighting a putative role for this cytokine in prostate cancer progression.

Indexed as

AnimalsApoptosisbcl-X ProteinBiomarkers, TumorCamptothecinCell DeathCell Line, TumorCell SurvivalCytokinesHumansMaleMiceNeoplasm ProteinsProstateProstatic NeoplasmsProto-Oncogene Proteins c-bcl-2BCL2L1 protein, humanBCL2 protein, humanbcl-X ProteinBiomarkers, TumorCamptothecinCytokinesFAM3B protein, humanNeoplasm ProteinsProto-Oncogene Proteins c-bcl-2Tumor Necrosis Factor-alphaApoptosisCytokinesFAM3BProstate cancerTumor growth

Identifiers

PMID29357840
PMCPMC5778767
OpenAlexW2784815833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.